AtriCure (ATRC) Stock: Buy, Sell, or Hold?
ATRC - AtriCure, Inc.
$54.54
1.58 (2.98%)
▲
5d:
+3.96%
30d:
+25.21%
90d:
+91.97%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When ATRC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ATRC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ATRC shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$21.02
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$13.05
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ATRC is currently trading at $54.54, which is considered extended relative to its 30-day fair value range of $41.92 to $50.89. From a valuation perspective, the stock is trading at a premium (Forward PE: 126.3) compared to its historical average (89.5). At these levels, the market is pricing in 12.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ATRC is in a strong uptrend. The price is approaching resistance at $55.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ATRC scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ATRC is in a strong uptrend. The price is approaching resistance at $55.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ATRC scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$41.92 -
$50.89
Company Quality Score
32/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
15.7%
All Signals
- BEARISH: Price extended above range (+7.2% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BEARISH: Trading above Wall St target ($51.67)
- NEUTRAL: Trading at premium valuation - market expects 12.2% growth which is achievable
- WARNING: Composite score 32/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$41.92 -
$50.89
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$46.61
Resistance Level
$55.72
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
126.31
Wall Street Target
$51.67
(-5.3%)
Revenue Growth (YoY)
12.8%
Profit Margin
1.8%
Valuation Premium vs History
+12.2% premium
PE vs Historical
126.3 vs 89.5
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+12.2%
(market-implied from PE analysis)
1-Year Target
$61.19
(+12%)
2-Year Target
$68.66
(+26%)
3-Year Target
$77.04
(+41%)
3-Yr Target (if PE normalizes)
(PE: 126→90)
PE COMPRESSION
$54.59
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 126.3, Growth: 51.9%)
$184.07
(+238%)
Base:
(SPY PE: 20.2, Growth: 51.9%)
$29.39
(-46%)
Bear:
(PE: 17.1, Growth: 51.9%)
$24.99
(-54%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (192x PE), but valuation improves significantly next year (126x PE) as earnings recover.
Forward PE: 192.31 | Forward EPS (Implied): $0.27
Bull Case
$62.21
(+21%)
Analyst growth 15.0%, PE expands to 201.9
Base Case
$51.52
(0%)
Market implied 0.0%, PE stable at 192.3
Bear Case
$39.41
(-24%)
Severe decline -15.0%, PE contracts to 173.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 12, 2026 9:35 AM ET
Data refreshes hourly during market hours. Next update: 10:35 AM
Data refreshes hourly during market hours. Next update: 10:35 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATRC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$478 | 53 HOLD |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$85 | 35 SELL |
|
WST
West Pharmaceutical Serv… |
STRONG BUY
13 analysts |
$405 | 63 BUY |
|
RGEN
Repligen Corporation |
STRONG BUY
19 analysts |
$188 | 45 HOLD |
|
RMD
ResMed Inc |
BUY
19 analysts |
$246 | 41 HOLD |
